Donate

Help us care for CaReMe patients


As a non-profit organisation, the CaReMe Global Alliance relies on the generosity of individuals and organisations to continue our independent work. An interdisciplinary, integrated Cardio, Renal and Metabolic Model of Care has been shown to improve outcomes, increase cost savings and enhance both resource utilisation and the patient’s treatment experience.

Having said that, the Global Alliance – and its novel approach to expanding the community of CaReMe clinics around the world – is still in its infancy. Your support can help us to grow faster and improve the lives of more people suffering from a combination of the debilitating CaReMe comorbidities.

You will be listed on our website accordingly, as you might like to be publicly acknowledged as a donor.

How to donate

Be it large or small, every donation makes a difference – and it only takes a few minutes to make an immediate payment online. You can use our secure payment gateway below or, if you prefer to make an electronic funds transfer, please do not hesitate to contact us.


Donate now

Did you know?


0123456789001234567890.01234567890

MILLION people worldwide die from cardiovascular disease annually1


012345678900123456789001234567890

MILLION people worldwide have chronic kidney disease2


012345678900123456789001234567890

MILLION adults worldwide have diabetes3


0123456789001234567890

% of chronic kidney disease patients have type-2 diabetes4


0123456789001234567890

% of type-2 diabetes-associated deaths are due to cardiovascular diseases5


0123456789001234567890.01234567890

% of people with diabetes have at least two comorbid conditions6


  1. World Health Organization. WHO World Heart Day 2017: Scale up prevention of heart attack and stroke: World Health Organization; 2017 [cited 2018 Jul 25].https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
  2. Hill NR, et al. Global prevalence of chronic kidney disease – A systematic review and meta-analysis. PLoS One [Internet]. 2016;10:1–18. http://dx.doi.org/10.1371/journal.pone.0158765.
  3. International Diabetes Federation. IDF Diabetes Atlas [Internet]. Ninth Edit. Karuranga S, Malanda B, Saeedi P, Salpea P, editors. 2019. 1–170 p. https://diabetesatlas.org/en/.
  4. Alicic RZ, et al. Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol [Internet]. 2017;12(18)2032-2045. https://cjasn.asnjournals.org/content/12/12/2032.
  5. Holman RR, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med [Internet]. 2008 Oct 9;359(15):1577–89. https://doi.org/10.1056/NEJMoa0806470.
  6. Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin [Internet]. 2016 Jul 2;32(7):1243–52. https://doi.org/10.1185/03007995.2016.1168291.









Copyright by CaReMe Global Alliance 2022. All rights reserved.



Copyright by CaReMe Global Alliance 2021. All rights reserved.